01PERCHE’ I NOSTRI SISTEMI

Le micro-nanoparticelle di silice mesoporosa sono le candidate ideali per lo sviluppo di sistemi per il direzionamento di farmaci, in quanto di facile sintesi, versatili, biocompatibili e sospendibili nei fluidi biologici.

Maggiori informazioni

02PERCHE’ LA NOSTRA AZIENDA

La NanoSiliCal Devices è uno spin off dell’Università della Calabria ed una start-up innovativa, fondata nel 2014 e finalizzata allo sviluppo di prodotti nano-strutturati in grado di rendere intelligenti le terapie antitumorali.

Maggiori informazioni

03PERCHE’ INVESTIRE

Il mercato delle biotecnologie è uno dei settori che sperimenta i più ampi fattori di crescita ed è destinato ad espandersi ulteriormente nei prossimi anni. NanoSiliCal Devices, per l’alto fattore di innovazione dei suoi prodotti, rappresenta una importante opportunità di investimento.

Maggiori informazioni

04LABORATORI

La sede operativa della NanoSiliCal Devices Srl è ospitata all’interno di una sezione del Dipartimento di Farmacia e Scienze della Salute e della Nutrizione appositamente dedicata al trasferimento tecnologico. I laboratori sono equipaggiati con tutte le attrezzature necessarie per la realizzazione di test chimico-fisici.

Maggiori informazioni

What makes us so specialOUR PRODUCTS

Our products technology is based on science of materials, providing nanostructured particles that can be administered intravenously, and, through the bloodstream, they can reach cancer cells, interact with them through a biological process and release a drug within. This leads to reduction of therapeutic doses, with a consequent therapeutic efficacy improvement and without toxic and side effects.

15Professional Staff
10Years of Experience
2patents granted
5financed projects (EU and local)
MSN carriers of a pro-drug and a targeting function

Mesoporous silica-based nanodevices (MSN) bearing a targeting molecule on the outer surface and an antineoplastic pro-drug linked within the pores by means of a pH-sensitive bond, as vehicles for targeting and release of biologically active molecules, are developed to be employed in targeted therapy. Suitable nanostructuring of matter better than with polymers because of nanoarchitecture and surface reactivity. Their pH-sensitive bond provides pro-drug (a biologically inactive form) delivery through the bloodstream (pH 7.4), until nanosystems reach the target tissue (pH 4-5), where they release the active form of the drug.

MSN for drug targeting with avidin-biotin system

Mesoporous silicas micro- or nanosystems anchored, through an avidin group, to a biotin-linked specific molecule (such as a monoclonal antibody, directed against a tumor marker). The system, conjugated to a drug with pH sensitive release control, is able to promote a ligand-mediated internalization into cells, causing their death.

Fluorescent MSNs for imaging diagnostics

Mesoporous silicas micro- or nano-systems linked with a highly specific ligand and a fluorescent marker that allows the visualization of target cells.

MSNs linked to plasmidic DNA

Mesoporous silicas micro- or nanosystems coupled to a specific functional group and with pores able to include plasmidic DNA, coding for proteins that have to be expressed in cellular systems (e.g. in basic experimental research), or in a specific organism, in case of deficits associated to a particular disease (gene therapy).

Our team

Our team is made of highly specialized professionals with many years of experience and education in their respective fields, who authored many publications and collaborated with many prominent institutions. Check this section to know more about our team

click here

Book recommendation

Update on Silica-Based Mesoporous Materials for Biomedical Applications Author: Luigi Pasqua; Publisher: Smithers Rapra Technology; 2011 ISBN 10: 1847355072 / ISBN 13: 9781847355072

from our blog LATEST NEWS

why you should choose our productsFEATURES OF OUR PRODUCTS

  1. 1
    Innovative and patentable

    Our products are innovative and patentable. It’s possible to acquire the license for the next clinical trials.

  2. 2
    Biobetters

    By using our systems (“biobetters”) there is a lower risk of failure compared to the so-called new chemical entities.

  3. 3
    Versatility

    Compared to other technologies currently in use (polymeric materials, liposomes, nanosomes), MSNs present an outer and an inner (pores walls) surface with high reactivity which can be functionalized using different molecules

  4. 4
    Easy synthesis process

    Easy synthesis process, which is ideal for an immediate scale-up.

  5. 5
    No interference

    Particles do not interfere with the therapeutic agents bound to the active surface

GET TO KNOW MORE ABOUT OUR PARTNERSOUR PARTNERS